Randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery; preliminary results of an RTOG study
Conference
·
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:5533778
- Univ. of Pennsylvania School of Medicine, Philadelphia
A randomized prospective was performed to evaluate misonidazole radiosensitized radiation therapy in the treatment of malignant glioma. The control arm, Group A, consisted of conventional radiation therapy (6000 cGy/6 to 7 weeks) to the whole brain plus BCNU (80 mg/m/sup 3/ on day 3, 4, 5, and then repeated q 8 weeks for 2 years). The BCNU schedule was identical in both arms. In the experimental arm, Group B, misonidazole 2.5 gm/m/sup 2/ was given once a week for six weeks, to a total dose of 15 gm/m/sup 2/. It was given orally four hours prior to 400 cGy on Mondays. On Tuesdays, Thursdays and Fridays, 150 cGy was delivered to a total of 5100 cGy/6 weeks. An additional 900 cGy/5F/1 week was given without misonidazole. Patients were stratified according to the prognostic factors of age, performance status, and histology. There is no significant difference in the survival of the two groups. The median survival for Group A was 12.6, and for Group B, 10.7 months. Misonidazole toxicity included an 11% peripheral neuropathy and a 3% central nervous system toxicity. BCNU toxicity included severe hematologic toxicity in 25%, including one death, and significant pulmonary toxicity in 6 out of 55 patients who received a minimum total dose of 960 mg/m/sup 2/ of BCNU.
- OSTI ID:
- 5533778
- Conference Information:
- Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 9:8
- Country of Publication:
- United States
- Language:
- English
Similar Records
Misonidazole and radiotherapy to treat malignant glioma: a Phase II trial of the radiation therapy oncology group
Large fraction radiotherapy plus misonidazole for treatment of advanced lung cancer: report of a phase I/II trial
Value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (number78-02)
Journal Article
·
Wed Dec 31 23:00:00 EST 1980
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6603383
Large fraction radiotherapy plus misonidazole for treatment of advanced lung cancer: report of a phase I/II trial
Journal Article
·
Sun Jan 31 23:00:00 EST 1982
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:6580912
Value of adjuvant misonidazole in the definitive irradiation of advanced head and neck squamous cancer: an RTOG pilot study (number78-02)
Journal Article
·
Mon Nov 30 23:00:00 EST 1981
· Int. J. Radiat. Oncol., Biol. Phys.; (United States)
·
OSTI ID:5855976
Related Subjects
550600 -- Medicine
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
560151 -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANTINEOPLASTIC DRUGS
AZOLES
BODY
BRAIN
CENTRAL NERVOUS SYSTEM
CHEMOTHERAPY
DISEASES
DRUGS
GLIOMAS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
IONIZING RADIATIONS
MEDICINE
MISONIDAZOLE
NEOPLASMS
NERVOUS SYSTEM
NITRO COMPOUNDS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
RADIATIONS
RADIOLOGY
RADIOSENSITIVITY EFFECTS
RADIOSENSITIZERS
RADIOTHERAPY
SURVIVAL TIME
THERAPY
TOXICITY
550603* -- Medicine-- External Radiation in Therapy-- (1980-)
560151 -- Radiation Effects on Animals-- Man
62 RADIOLOGY AND NUCLEAR MEDICINE
63 RADIATION, THERMAL, AND OTHER ENVIRON. POLLUTANT EFFECTS ON LIVING ORGS. AND BIOL. MAT.
ANTINEOPLASTIC DRUGS
AZOLES
BODY
BRAIN
CENTRAL NERVOUS SYSTEM
CHEMOTHERAPY
DISEASES
DRUGS
GLIOMAS
HETEROCYCLIC COMPOUNDS
IMIDAZOLES
IONIZING RADIATIONS
MEDICINE
MISONIDAZOLE
NEOPLASMS
NERVOUS SYSTEM
NITRO COMPOUNDS
NUCLEAR MEDICINE
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
RADIATIONS
RADIOLOGY
RADIOSENSITIVITY EFFECTS
RADIOSENSITIZERS
RADIOTHERAPY
SURVIVAL TIME
THERAPY
TOXICITY